| 生物制药创新失败药物挽救路径研究及其管理启示 |
| |
| 引用本文： | 董晓东,李天柱,宋丹荣.生物制药创新失败药物挽救路径研究及其管理启示[J].科技管理研究,2019,39(6):128-135. |
| |
| 作者姓名： | 董晓东 李天柱 宋丹荣 |
| |
| 作者单位： | 辽宁科技大学工商管理学院,辽宁鞍山,114051;辽宁科技大学工商管理学院,辽宁鞍山,114051;辽宁科技大学工商管理学院,辽宁鞍山,114051 |
| |
| 基金项目： | (71472080) 生物制药创新失败药物挽救机制研究 |
| |
| 摘 要： | 以生物制药产业为背景,采取案例研究方法,瞄准沙利度胺、伟哥等四种经历失败重获新生的创新药物为研究对象,回溯其"失败-成功"的重生过程,抽象归纳"科学家(大学、科研院所)—大企业合作-核心公司""科学家(专家型公司)—核心公司—专家型公司逐步内化为核心公司"及"科学家(核心公司)—核心公司全面行动"三种典型挽救路径,进而针对生物制药创新各方及失败药物挽救各参与方提出多种管理启示。
|
| 关 键 词： | 生物制药 挽救路径 管理启示 |
| 收稿时间： | 2018/5/8 0:00:00 |
| 修稿时间： | 2018/6/25 0:00:00 |
Study on the rescued paths of failed biopharmaceutical drug innovation and its revelation |
| |
| Dong Xiaodong,Li Tianzhu,Song Danrong.Study on the rescued paths of failed biopharmaceutical drug innovation and its revelation[J].Science and Technology Management Research,2019,39(6):128-135. |
| |
| Authors: | Dong Xiaodong Li Tianzhu Song Danrong |
| |
| Institution: | (School of Business Administration,University of Science and Technology Liaoning,Anshan 114051,China) |
| |
| Abstract: | Under the background of biotechnology pharmaceutical industries, the paper takes a case study method, aiming at four kinds of innovative drugs that have failed to regenerate, such as Thalidomide and Viagra, backtracks the rebirth process of "failure and success", and abstractly sums up three typical rescue paths such as "Scientists(universities, scientific research institutes)-Big Enterprise Cooperation-Core Company","Scientist(Expert Company)-Core Company-Expert Company which is then gradually internalized into Core Company " and "Scientist(Core Company)– its Comprehensive Action ". At last, multiple management revelations for all parties involved in biopharmaceutical innovation and failed drug recovery are put forward. |
| |
| Keywords: | Biopharmaceuticals Rescue Path Management Revelations |
| 本文献已被 维普 万方数据 等数据库收录！ |
| 点击此处可从《科技管理研究》浏览原始摘要信息 |
| 点击此处可从《科技管理研究》下载免费的PDF全文 |
|
